

09/802, 508

7-26-01

Individual Applicant

Street :
City : Athens
State : GA
Country : USA
PostalCode : 30602-7272
PhoneNumber : 706-542-0928
FaxNumber : ____-_____
EmailAddress : wparrott@uga.edu
<110> LastName : Parrott
<110> FirstName : Wayne
<110> MiddleInitial : A
<110> Suffix : PhD.

Does Not Comply
Corrected Diskette Needed

(This page shown as
sample of
submitted file)

Individual Applicant

Street :
City : Athens
State : GA
Country : USA
PostalCode : 30602-7272
PhoneNumber : 706-542-0928
FaxNumber : ____-_____
EmailAddress :
<110> LastName : LaFayette
<110> FirstName : Peter
<110> MiddleInitial : R
<110> Suffix : PhD.

Individual Applicant

Street : 1907 South Milledge Ave
City : Athens
State : GA
Country : USA
PostalCode : 30605-_____
PhoneNumber : ____-_____
FaxNumber : ____-_____
EmailAddress :
<110> LastName : Kane
<110> FirstName : Patrick
<110> MiddleInitial : M
<110> Suffix :

All sample
Sequence Listing
(attached) for
valid format

Application Project

<120> Title : Arabitol or Ribitol As Positive Selectable Markers
<130> AppFileReference : UGA-855R
<140> CurrentAppNumber :
<141> CurrentFilingDate : ____-____-

Sequence

<213> OrganismName : Escherichia coli
<400> PreSequenceString :
atgaacgaac aatttacatg gctgcacatc gggtaggtt ctttcatcg cgcacatcg

Please consult

<110> Smith, John; Smithgene Inc.
<120> Example of a Sequence Listing
<130> 01-00001
<140> PCT/EP98/00001
<141> 1998-12-31
<150> US 08/999,999
<151> 1997-10-15
<160> 4
<170> PatentIn version 2.0
<210> 1
<211> 389
<212> DNA
<213> Paramecium sp.
<220>
<221> CDS
<222> (279)...(389)
<300>
<301> Doe, Richard
<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.
<303> Journal of Genes
<304> 1
<305> 4
<306> 1-7
<307> 1988-06-31
<308> 123456
<309> 1988-06-31

<400> 1 agctgtatgc attcctgtgt cctcttctct ctgggtttct caccctgtca atcagatctc 60
aggagagtg tcttgaccct cctctgcctt tgca gttca caggcaggca ggcaggcagc 120
tgatgtggca attgctggca gtgccacagg cttttcagcc aggcttaggg tgggtccgc 180
cgccccgcgg cggccctct cgcgttctc tcgcgcctct ctctcgctc cctctcgctc 240

Appendix 3, page 2

ggacctgatt aggtgagcag gaggaggggg cagttgc atg gtt tca atg ttc agc 296
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Met Phe Ser 1 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100

ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgt ttg ttc 344
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Gln 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389
Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Leu 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu 1 5 10 15
Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3
Met Val Asn Leu Glu Pro Met His Thr Glu Ile 1 5 10

<210> 4
<400> 4
000

(Annex VIII follows)

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other- Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOS	Count includes total number of SEQ ID NOS	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	O
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	O
<302>	Title		O
<303>	Journal		O
<304>	Volume		O
<305>	Issue		O
<306>	Pages		O
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	O
<308>	Database Accession Number	Accession number assigned by database including database name	O
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	O
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	O

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	O
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd.	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;